practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been
Search Results
Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017
William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar
®. P <.001), PFS (not reached in the idelalisib group vs 5.5 months for placebo), and OS at 12 months (92% vs 80%; P =.02) compared with rituximab plus placebo. Grade 3 or 4 AEs (pneumonia, pyrexia, and febrile neutropenia) were reported in 40% of
New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective
Dawn Goetz
seen grade 3 or 4 adverse effects are neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, fatigue, and asthenia. The approximate neutrophil nadir is 12 days, and cabazitaxel carries a black box warning against giving the drug to patients
Part 2: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium
Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?
Edmond Marzbani and Elihu Estey
, 6 patients were admitted for febrile neutropenia, and 3 cases of nonfatal Pneumocystis jiroveci were seen. 13 , 14 In a Japanese case series of 10 patients, a less-intensive regimen of ATRA, 6-MP, and MTX was used for maintenance, and no patients
Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
neutropenia (grade 3: 69%; grade 4: 29%), febrile neutropenia (8%), thrombocytopenia (37%), and anemia (25%). Seven patients experienced treatment-related serious AEs, with 1 grade 5 event. Of the evaluable patients, 80% and 7% achieved clinical complete and
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera
overall and grade 3/4 toxicities in comparison with doublets ( Table 3 ), particularly with more grade 3/4 anemia, stomatitis, febrile neutropenia (10.4% vs 6.5%), hepatic toxicity (15.8% vs 9.2%), and toxicity-related hospitalization (30.7% vs 22
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
-line FOLFIRINOX. After 38 weeks, imaging again showed progression of hepatic metastases. He received third-line therapy with docetaxel and irinotecan for 2 weeks, but this therapy was complicated by febrile neutropenia. A tumor specimen from the
Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass
risk. 61 PLWH may be more susceptible to infectious complications after chemotherapy than their uninfected counterparts, 62 and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 63 Furthermore, data show that certain
AIDS-Related Kaposi Sarcoma, Version 2.2019
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass
uninfected counterparts to infectious complications after chemotherapy, and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 47 Furthermore, data show that certain chemotherapy regimens can cause a sustained drop in CD4+ T